Executive Director, Private Equity, Sofinnova Ventures
David Kabakoff has been an Executive Partner with Sofinnova since 2007 and a Partner in HealthQuest Capital since 2013. Prior to entering venture capital, David had more than 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, diagnostics, and drug delivery fields. David currently serves as Chairman of NextCure, Chairman of Lineagen, as a Director of Antiva Biosciences, Dauntless Pharmaceuticals, Principia Biosciences, BioClin Therapeutics, Castle Biosciences and BioTheranostics. Formerly he served as Chairman of Trius Therapeutics (acquired by Cubist), Chairman of Amplimmune (acquired by Astra Zeneca), as a Director of InterMune, Inc. (acquired by Roche), and Director of Allylix, Inc. (acquired by Evolva). Dr. Kabakoff also served as a Board Observer at Intellikine (acquired by Takeda).
David co-founded Salmedix, Inc., a developer of cancer drugs, and served as Chairman and Chief Executive Officer (acquired by Cephalon Inc.). David also held the positions of Executive Vice President of Dura, a specialty respiratory pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development Corp. Prior to Dura, David was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.
David received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.